ALPMY:OTC-Astellas Pharma Inc (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 16.14

Change

+0.19 (+1.19)%

Market Cap

USD 29.61B

Volume

0.09M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ALPMY Stock Forecast & Price:
Based on the Astellas Pharma Inc stock forecasts from 0 analysts, the average analyst target price for Astellas Pharma Inc is not available over the next 12 months. Astellas Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Astellas Pharma Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Astellas Pharma Inc’s stock price was USD 16.14. Astellas Pharma Inc’s stock price has changed by +7.67% over the past week, +1.13% over the past month and -11.07% over the last year.

No recent analyst target price found for Astellas Pharma Inc
No recent average analyst rating found for Astellas Pharma Inc

About Astellas Pharma Inc (ALPMY:OTC)

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid le ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-28 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBF Roche Holding AG

N/A

USD335.66B 23.42 14.85
RHHBY Roche Holding Ltd ADR

-0.86 (-2.04%)

USD329.54B 20.11 14.85
RHHVF Roche Holding AG Participation

+0.15 (+0.05%)

USD327.49B 19.62 14.85
AZNCF AstraZeneca PLC

+4.45 (+3.50%)

USD201.89B 1,636.08 30.94
NVSEF Novartis AG

+0.84 (+1.00%)

USD192.57B 7.83 5.85
SNYNF Sanofi

N/A

USD133.41B 18.63 13.35
GLAXF GSK plc

N/A

USD107.27B 17.02 12.87
BAYZF Bayer Aktiengesellschaft

N/A

USD62.49B 25.99 12.93
BAYRY Bayer AG PK

+0.09 (+0.58%)

USD61.20B 26.02 12.93
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.06 (-0.45%)

USD44.47B 15.26 0.07

ETFs Containing ALPMY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.80% 60% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.80% 50% F 68% D+
Trailing 12 Months  
Capital Gain -9.03% 51% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.03% 47% F 65% D
Trailing 5 Years  
Capital Gain 33.78% 71% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.78% 68% D+ 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 5.93% 69% D+ 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.93% 56% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 14.19% 81% B- 90% A-
Risk Adjusted Return 41.75% 58% F 69% D+
Market Capitalization 29.61B 61% D- 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.94 26% F 18% F
Price/Book Ratio 2.63 50% F 33% F
Price / Cash Flow Ratio 0.12 83% B 48% F
EV/EBITDA 0.11 64% D 80% B-
Management Effectiveness  
Return on Equity 8.72% 47% F 58% F
Return on Invested Capital 6.90% 44% F 61% D-
Return on Assets 4.85% 44% F 79% C+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 2.66% 43% F 35% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.64 33% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector